Navigation Links
Biologics-naive juvenile idiopathic arthritis patients have elevated risk of cancer
Date:6/17/2010

Rome, Italy, Thursday 17 June 2010: Biologics-nave Juvenile Idiopathic Arthritis (JIA) patients may have an increased risk of cancer compared with the general Swedish population, according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Results of an additional study, which researched a small cohort of patients showed an increased frequency of cancer in those receiving the biologic etanercept, however, results were deemed not statistically significant by researchers.

The results of a population-based Swedish cohort study found that the incidence of cancer among paediatric patients with JIA identified during the last 40 years was comparable to that seen in the general population, (0.5 vs. 0.4 cases per 1000 person years, Relative Risk (RR)=1.1, 95%CI 0.9-1.5). Subset analyses however indicated that subjects diagnosed with JIA since 1987 (the year that the Swedish patient registry attained nationwide coverage) were at elevated risk of developing cancer (RR=2.3, 95%CI 1.2-4.4, 13 JIA cancers vs. 30 in comparator), attributed to an increased occurrence of cancers of the lymphatic system (RR=4.2, 95%CI 1.7-10.7, 8 cancers in JIA vs. 10 in comparator).

"These results are intriguing and suggest that in the past 20 years, patients with JIA not treated with biological therapies appear to have an elevated risk of cancer compared with the general population," said lead author of the study Dr. Julia Simard, Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden. "The results of our study indicate that evaluation of cancer risks with biologics in paediatric populations need to factor in differences in incidence of cancer between these patients and the general population. From a clinical point of view, it should be remembered that although we noted an increased risk in relative terms, the excess risks remain low in absolute terms."

The Swedish study assessed a national JIA cohort of 9,020 patients. For each JIA patient, up to five general-population comparators were identified (n=44,858). In the biologics-nave JIA cohort, 60 cancers were observed during 131,144 person-years compared to 266 cancers during 661,758 person-years in the population comparator. Researchers noted that sensitivity analyses did not reveal an explanation for the differences seen between patients identified before and after 1987.

The results of the second study combined data on 1,721 patients treated with etanercept from three prospective JIA registries in Germany, the UK and the US. Of the 1,641 patients who qualified for the primary analysis, two cancers were reported. Whilst this yielded a rate higher than expected when compared to the general population, it was not statistically significant (RR estimated using a Standardized Incident Ratio (SIR) of 3.7 (0.5-13.4, 95%CI)). This is believed to be in part due to the low event rate. The interpretation of these findings may be further limited by the fact that the comparator rates were based on a general population and not a biologics-nave JIA population, as per the Swedish study, which suggests this may indicate an increased underlying risk of cancer.


'/>"/>

Contact: Caroline Butt
eularpressoffice@uk.cohnwolfe.com
44-778-927-0392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. BestofNorthCarolina.com Presents Their Inaugural 'Carolina Beach Bash' to Benefit the Juvenile Diabetes Research Foundation
2. Most states offer HPV vaccinations to girls in juvenile justice system
3. Montreal researchers shed light on common juvenile cancer
4. Diffuse idiopathic skeletal hyperostosis causes dysphagia in older patients
5. Arthritis simulation gloves aid companies in designing easy-to-use products
6. Long Before Symptoms, Blood May Reveal Rheumatoid Arthritis
7. Biomarker could help doctors tailor treatment for rheumatoid arthritis
8. Vibrant Health Co Sponsors Specialty Arthritis Pain Relief Blog, painreliefcream.info
9. Blood test can predict rheumatoid arthritis before symptoms arise
10. Rheumatoid arthritis doesnt hinder computing skills
11. How arthritis thrives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: